PODD — Insulet Corporation
Is PODD overbought or oversold? Here is the current MarketMoodz read.
Insulet Corporation (PODD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $145.29. The rating moved from Overbought to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$145.29
- Last changeMoved from Overbought to Oversold on November 17, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Insulet’s tubeless Omnipod system and growing closed‑loop integrations underpin recurring revenue and elevated customer retention, supporting above‑market growth potential. Near‑term dynamics include cautious market sentiment and healthcare reimbursement scrutiny, but the company’s market share gains, international expansion, and margin improvement trajectory provide constructive catalysts. Key near‑ and medium‑term risks include competitive pressure, reimbursement/regulatory shifts, and the longer‑term impact of obesity/GLP‑1 therapies on insulin demand.
Key factors
- Distinct product differentiation with tubeless Omnipod platform and sticky recurring consumable revenue stream
- Expanding closed‑loop integrations with major CGM partners improving clinical value and customer retention
- Strong U.S. market share gains and ongoing international expansion opportunities
- Favorable long‑term diabetes prevalence and insulin demand tailwinds supporting secular growth
- Operational leverage potential as revenue scales and gross margin improvements continue
Risks
- Rapid uptake of GLP‑1/obesity therapies could reduce insulin needs among some type 2 patients over time
- Reimbursement and Medicare policy changes (including Medicare Advantage integrity actions) could pressure access and pricing for diabetes devices and supplies
- Intense competition from established insulin pump and integrated system suppliers (Medtronic, Tandem, others)
- Execution risk around manufacturing scale, supply chain disruptions, or regulatory setbacks for product updates
- Currency exposure and potential slower adoption in certain international markets
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for PODD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.